2014
Tapered withdrawal of phenytoin removes protective effect in EAE without inflammatory rebound and mortality
Liu S, Zwinger P, Black JA, Waxman SG. Tapered withdrawal of phenytoin removes protective effect in EAE without inflammatory rebound and mortality. Journal Of The Neurological Sciences 2014, 341: 8-12. PMID: 24690348, DOI: 10.1016/j.jns.2014.03.029.Peer-Reviewed Original ResearchConceptsExperimental autoimmune encephalomyelitisSodium channel blockersImmune cell infiltratesMultiple sclerosisChannel blockersNeurological deficitsPhenytoin treatmentCell infiltrateTapered withdrawalTreatment of MSModel of MSSudden withdrawalMassive inflammatory infiltrateNon-treated levelsPotential therapeutic agentInflammatory reboundSevere exacerbationsAutoimmune encephalomyelitisNeuroprotective therapiesInflammatory infiltrateClinical scoresAbrupt withdrawalProtective effectHigh mortalityInfiltrates
2007
Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine
Black JA, Liu S, Carrithers M, Carrithers LM, Waxman SG. Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine. Annals Of Neurology 2007, 62: 21-33. PMID: 17654737, DOI: 10.1002/ana.21172.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnticonvulsantsAntigens, CDAxonsCarbamazepineCell CountDisease Models, AnimalEncephalomyelitis, Autoimmune, ExperimentalFlow CytometryGene Expression RegulationGlycoproteinsMiceMice, Inbred C57BLMyelin-Oligodendrocyte GlycoproteinNAV1.6 Voltage-Gated Sodium ChannelNerve Tissue ProteinsPeptide FragmentsPhenytoinPyramidal TractsSeverity of Illness IndexSodium ChannelsSubstance Withdrawal SyndromeConceptsExperimental autoimmune encephalomyelitisSodium channel blockersWithdrawal of phenytoinChannel blockersAutoimmune encephalomyelitisInflammatory infiltrateClinical studiesProtective effectMurine experimental autoimmune encephalomyelitisWithdrawal of carbamazepineCentral nervous system axonsCentral nervous systemAcute exacerbationAcute worseningClinical worseningEAE symptomsEAE miceNeuroinflammatory disordersClinical courseMyelin oligodendrocyteClinical statusControl miceMultiple sclerosisImmune cellsLong-term effects
2006
Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE
Black JA, Liu S, Hains BC, Saab CY, Waxman SG. Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE. Brain 2006, 129: 3196-3208. PMID: 16931536, DOI: 10.1093/brain/awl216.Peer-Reviewed Original ResearchMeSH KeywordsAction PotentialsAdministration, OralAnimalsAxonsCell CountCervical VertebraeChronic DiseaseEncephalomyelitis, Autoimmune, ExperimentalImmunohistochemistryInjections, SubcutaneousMiceMice, Inbred C57BLMyelin ProteinsMyelin-Associated GlycoproteinMyelin-Oligodendrocyte GlycoproteinNeural ConductionPhenytoinRecurrenceSodium Channel BlockersSpinal CordTreatment OutcomeConceptsExperimental autoimmune encephalomyelitisC57/BL6 miceChronic-relapsing experimental autoimmune encephalomyelitisBL6 miceLong-term protectionAxonal degenerationClinical statusDays post-EAE inductionMurine experimental autoimmune encephalomyelitisLong-term protective effectPhenytoin-treated miceInflammatory cell infiltrationDorsal column axonsCompound action potentialSodium channel blockersAutoimmune encephalomyelitisAxonal lossPhenytoin treatmentUntreated miceNeuroinflammatory diseasesDorsal columnsMultiple sclerosisCNS injuryCell infiltrationCorticospinal tract